Agenda
Synopsis
Conférenciers
Favoris
Documents
Revenir à l'agenda
Myriam LAMAMRI
Clichy, France
Session(s)
Réanimation - fonction rénale
, Orateur(s) - 17/09/2025 - 10:30 - 12:00 - 212-213
Safety concern with high continuous dose of cefepime among critically ill patients with impaired to augmented renal clearance at a level 1 trauma center: CEFTOX Study
Concours des résidents
, Orateur(s) - 17/09/2025 - 14:30 - 18:00 - 243
Safety concern with high continuous dose of cefepime among critically ill patients with impaired to augmented renal clearance at a level 1 trauma center: CEFTOX Study
'%20fill='%232c3e50'%20fill-rule='evenodd'/%3e%3c/svg%3e)
'%3e%3cg%20id='Ellipse_2'%20data-name='Ellipse%202'%20transform='translate(-1.77%20-1.77)'%20fill='none'%20stroke='%23ecf0f1'%20stroke-width='3'%3e%3ccircle%20cx='60.5'%20cy='60.5'%20r='60.5'%20stroke='none'/%3e%3ccircle%20cx='60.5'%20cy='60.5'%20r='59'%20fill='none'/%3e%3c/g%3e%3cpath%20id='Path_1011'%20data-name='Path%201011'%20d='M85.809,84.571c-2.161-2.849-5.489-4.45-9.9-4.785a2.127,2.127,0,0,1-1.88,1.16H70.336a2.156,2.156,0,0,1,0-4.312h3.694a2.126,2.126,0,0,1,2.023,1.516c4.889.372,8.609,2.188,11.065,5.428,2.727,3.6,3.444,8.327,3.409,12.47h14.228a58.947,58.947,0,1,0-91.611.005H88.868C88.9,92.181,88.259,87.8,85.809,84.571ZM58.949,22.757A20.034,20.034,0,1,1,38.915,42.791,20.033,20.033,0,0,1,58.949,22.757ZM29.509,82.3A22.137,22.137,0,0,1,45.989,60.944a18.93,18.93,0,0,0,25.922,0,22.2,22.2,0,0,1,15.47,14.822l.921,4.586c.011.1.005.21.013.313a17.223,17.223,0,0,0-10.539-5.088A5,5,0,0,0,74.032,73.9H70.338a5.07,5.07,0,0,0,0,10.141h3.694a4.982,4.982,0,0,0,3.017-1.017A9.434,9.434,0,0,1,83.488,86.5a13.551,13.551,0,0,1,2.339,6.8H29.509Z'%20transform='translate(-0.236%20-0.236)'%20fill='%232c3e50'/%3e%3cpath%20id='Path_1012'%20data-name='Path%201012'%20d='M166.585,125.767a20.034,20.034,0,1,0-20.035-20.032A20.033,20.033,0,0,0,166.585,125.767Z'%20transform='translate(-107.871%20-63.179)'%20fill='%23ecf0f1'/%3e%3cpath%20id='Path_1013'%20data-name='Path%201013'%20d='M165.1,255.081a9.439,9.439,0,0,0-6.439-3.484,4.982,4.982,0,0,1-3.017,1.017h-3.694a5.07,5.07,0,0,1,0-10.141h3.694a5,5,0,0,1,3.744,1.681,17.224,17.224,0,0,1,10.539,5.088c-.008-.1-.005-.21-.013-.313l-.921-4.586a22.191,22.191,0,0,0-15.47-14.822,18.93,18.93,0,0,1-25.922,0,22.135,22.135,0,0,0-16.479,21.357v11.007h56.315A13.492,13.492,0,0,0,165.1,255.081Z'%20transform='translate(-81.849%20-168.809)'%20fill='%23ecf0f1'/%3e%3cpath%20id='Path_1014'%20data-name='Path%201014'%20d='M95.305,329.872a58.831,58.831,0,0,0,45.808-21.848H126.886c.035-4.142-.682-8.872-3.41-12.47-2.456-3.24-6.176-5.056-11.065-5.428a2.129,2.129,0,0,0-2.023-1.516h-3.694a2.156,2.156,0,0,0,0,4.312h3.694a2.127,2.127,0,0,0,1.88-1.16c4.411.335,7.738,1.936,9.9,4.785,2.451,3.232,3.1,7.61,3.059,11.482H49.5A58.833,58.833,0,0,0,95.305,329.872Z'%20transform='translate(-36.591%20-212.209)'%20fill='%23ecf0f1'/%3e%3c/g%3e%3c/svg%3e)
'%3e%3cline%20id='Line_151'%20data-name='Line%20151'%20x2='29.522'%20transform='translate(22.5%2022.368)'%20fill='none'%20stroke='%23fff'%20stroke-linecap='round'%20stroke-width='4'/%3e%3cline%20id='Line_152'%20data-name='Line%20152'%20x2='29.522'%20transform='translate(22.5%2032.443)'%20fill='none'%20stroke='%23fff'%20stroke-linecap='round'%20stroke-width='4'/%3e%3cline%20id='Line_153'%20data-name='Line%20153'%20x2='29.522'%20transform='translate(22.5%2042.519)'%20fill='none'%20stroke='%23fff'%20stroke-linecap='round'%20stroke-width='4'/%3e%3c/g%3e%3c/svg%3e)